文献速递类风湿关节炎

持续低疾病活动度的类风湿关节炎患者10年结局相似,与初始治疗无关

Rheumatoid arthritis patients with continued low disease activity have similar outcomes over 10 years, regardless of initial therapy.
PubMed 文献 · Rheumatology (Oxford) · 2017-01-01

本研究基于BeSt研究10年随访数据,比较持续低疾病活动度且接受甲氨蝶呤单药或初始联合英夫利西单抗/泼尼松+柳氮磺吡啶治疗的RA患者。结果显示联合治疗组更多患者达到持续低疾病活动度,但长期结局无额外获益,仅甲氨蝶呤单药组无药缓解比例更高。

要点

  • 初始联合治疗组持续低疾病活动度比例更高(26% vs 11%),但长期结局无额外获益。
  • 持续低疾病活动度患者10年DAS、HAQ等结局组间差异临床可忽略。
  • 甲氨蝶呤单药组无药缓解比例更高。

核心结论

  • 初始泼尼松或英夫利西单抗联合治疗比初始甲氨蝶呤单药有更多患者达到持续低疾病活动度,但无额外长期获益。
  • 无论诱导治疗如何,持续低疾病活动度患者长期结局相似,仅甲氨蝶呤单药组无药缓解比例更高。

研究设计与样本

  • 分析BeSt研究中有10年随访的近期起病RA患者,治疗 tightly controlled 目标DAS≤2.4。
  • 选取从6个月至10年持续低疾病活动度且未强化治疗的患者,分为甲氨蝶呤单药组和初始联合治疗组。
  • 采用(广义)线性混合模型分析组间随时间差异。

主要发现

  • 10年时,甲氨蝶呤单药组28/247(11%)患者持续DAS≤2.4,联合治疗组68/261(26%)患者持续DAS≤2.4。
  • 持续应答者组间随时间无差异,仅甲氨蝶呤单药组无药缓解比例更高。
  • DAS、ESR和患者总体健康视觉模拟评分存在显著组-时间交互,但结果临床可忽略。

关键数值与推荐

  • 持续低疾病活动度定义为从6个月至10年DAS≤2.4。
  • 结局包括DAS、HAQ、ESR、患者总体健康视觉模拟评分、无药缓解比例和Sharp/van der Heijde评分进展≥5的患者比例。

临床怎么用

  • 对于达到持续低疾病活动度的RA患者,初始联合治疗与甲氨蝶呤单药的长期结局相似,无需因初始治疗不同而改变后续管理。
  • 甲氨蝶呤单药治疗达到持续低疾病活动度者更可能实现无药缓解。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare 10-year disease outcomes of RA patients who have continuous low disease activity and are on MTX with or without initial combination therapy with infliximab or prednisone and SSZ. METHODS: Recent-onset RA patients from the Behandel Strategieen (BeSt) (Dutch acronym for Treatment Strategies) study with 10 years of follow-up were analysed. Treatment was tightly controlled, targeted at DAS ⩽ 2.4. The selected patients had low disease activity from 6 months until 10 years and therefore did not intensify treatment. Patients were grouped into those receiving MTX monotherapy and those receiving initial combination therapy. Between-group differences over time were compared, using (generalized) linear mixed model analyses, for the outcomes DAS, HAQ, ESR, visual analogue scale patient global health, percentage of patients in (drug-free) remission and percentage of patients with Sharp/van der Heijde score progression ⩾5. RESULTS: At 10 years, 28/247 (11%) patients on MTX monotherapy (some tapered to drug free) had continued DAS ⩽ 2.4 compared with 68/261 (26%) patients on combination therapy (all tapered to monotherapy or drug free). No between-group differences in continuous responders were found over time, except for a higher percentage of patients in drug-free remission after MTX monotherapy. Significant group-time interactions were found for DAS, ESR and visual analogue scale patient global health, but the results seem clinically negligible. CONCLUSION: More patients achieved continuous low disease activity on initial prednisone or infliximab combination therapy than on initial MTX monotherapy, but there appeared to be no additional benefits. Regardless of induction therapy, patients with continuous low disease activity have similar long-term outcomes, with only a higher proportion of patients in drug-free remission after MTX monotherapy.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Bergstra SA, Landewé RBM, Huizinga TWJ, et al. Rheumatoid arthritis patients with continued low disease activity have similar outcomes over 10 years, regardless of initial therapy. Rheumatology (Oxford). 2017. PMID: 28957556. doi:10.1093/rheumatology/kex236

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。